Werewolf Therapeutics FY2025 net loss narrows 13.76% to $61 million; cash and cash equivalents drop 48.6% to $57 million

Reuters03-27

Werewolf <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net loss narrows 13.76% to $61 million; cash and cash equivalents drop 48.6% to $57 million

Werewolf published a quarterly and annual earnings press release reporting Q4 and FY 2025 results and a strategic review process to maximize stockholder value, including potential sale, merger, asset sale, or licensing/collaboration.
Q4 net loss was USD 8.4 million, a 58.92% narrowing, and R&D expense was USD 6.9 million, down 55.92%.
G&A expense in Q4 was USD 2.5 million, down 46.23%, and cash and cash equivalents were USD 57.1 million as of Dec. 31, 2025.
FY net loss was USD 60.8 million, a 13.74% narrowing, and FY R&D expense was USD 44.8 million, down 20.55%.
The company said its cash position is expected to fund operating expenses and capital requirements into Q4 2026, and it engaged Piper Sandler as exclusive financial advisor for the strategic evaluation process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679265) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622233108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622233108","market":"us","top_or_hot":-1,"title":"Werewolf Therapeutics FY2025 net loss narrows 13.76% to $61 million; cash and cash equivalents drop 48.6% to $57 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Werewolf <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net loss narrows 13.76% to $61 million; cash and cash equivalents drop 48.6% to $57 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Werewolf published a quarterly and annual earnings press release reporting Q4 and FY 2025 results and a strategic review process to maximize stockholder value, including potential sale, merger, asset sale, or licensing/collaboration.\n        </li>\n<li>\n          Q4 net loss was USD 8.4 million, a 58.92% narrowing, and R&amp;D expense was USD 6.9 million, down 55.92%.\n        </li>\n<li>\n          G&amp;A expense in Q4 was USD 2.5 million, down 46.23%, and cash and cash equivalents were USD 57.1 million as of Dec. 31, 2025.\n        </li>\n<li>\n          FY net loss was USD 60.8 million, a 13.74% narrowing, and FY R&amp;D expense was USD 44.8 million, down 20.55%.\n        </li>\n<li>\n          The company said its cash position is expected to fund operating expenses and capital requirements into Q4 2026, and it engaged Piper Sandler as exclusive financial advisor for the strategic evaluation process.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679265) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Werewolf Therapeutics FY2025 net loss narrows 13.76% to $61 million; cash and cash equivalents drop 48.6% to $57 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWerewolf Therapeutics FY2025 net loss narrows 13.76% to $61 million; cash and cash equivalents drop 48.6% to $57 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Werewolf <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net loss narrows 13.76% to $61 million; cash and cash equivalents drop 48.6% to $57 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Werewolf published a quarterly and annual earnings press release reporting Q4 and FY 2025 results and a strategic review process to maximize stockholder value, including potential sale, merger, asset sale, or licensing/collaboration.\n        </li>\n<li>\n          Q4 net loss was USD 8.4 million, a 58.92% narrowing, and R&amp;D expense was USD 6.9 million, down 55.92%.\n        </li>\n<li>\n          G&amp;A expense in Q4 was USD 2.5 million, down 46.23%, and cash and cash equivalents were USD 57.1 million as of Dec. 31, 2025.\n        </li>\n<li>\n          FY net loss was USD 60.8 million, a 13.74% narrowing, and FY R&amp;D expense was USD 44.8 million, down 20.55%.\n        </li>\n<li>\n          The company said its cash position is expected to fund operating expenses and capital requirements into Q4 2026, and it engaged Piper Sandler as exclusive financial advisor for the strategic evaluation process.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679265) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL43myKY:1","article_id":"2622233108","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622233108","pubTimestamp":1774609321,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Q4 net loss was USD 8.4 million, a 58.92% narrowing, and R&D expense was USD 6.9 million, down 55.92%.G&A expense in Q4 was USD 2.5 million, down 46.23%, and cash and cash equivalents were USD 57.1 million as of Dec. 31, 2025.FY net loss was USD 60.8 million, a 13.74% narrowing, and FY R&D expense was USD 44.8 million, down 20.55%.The company said its cash position is expected to fund operating expenses and capital requirements into Q4 2026, and it engaged Piper Sandler as exclusive financial advisor for the strategic evaluation process.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HOWL":"Werewolf Therapeutics, Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4539":"次新股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","PIPR":"派杰投资","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK4127":"投资银行业与经纪业"},"translate_title":"Werewolf Therapeutics 2025财年净亏损收窄13.76%至6100万美元；现金及现金等价物下降48.6%至5700万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PIPR":0.9,"HOWL":0.9},"content_text":"Werewolf Therapeutics FY2025 net loss narrows 13.76% to $61 million; cash and cash equivalents drop 48.6% to $57 million\n    \n\n\n          Werewolf published a quarterly and annual earnings press release reporting Q4 and FY 2025 results and a strategic review process to maximize stockholder value, including potential sale, merger, asset sale, or licensing/collaboration.\n        \n\n          Q4 net loss was USD 8.4 million, a 58.92% narrowing, and R&D expense was USD 6.9 million, down 55.92%.\n        \n\n          G&A expense in Q4 was USD 2.5 million, down 46.23%, and cash and cash equivalents were USD 57.1 million as of Dec. 31, 2025.\n        \n\n          FY net loss was USD 60.8 million, a 13.74% narrowing, and FY R&D expense was USD 44.8 million, down 20.55%.\n        \n\n          The company said its cash position is expected to fund operating expenses and capital requirements into Q4 2026, and it engaged Piper Sandler as exclusive financial advisor for the strategic evaluation process.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679265) on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622233108","isCrawlerRequest":true}